Add to ORKGBackground: Results of a clinical trial recently completed in the United States indicate that administration of tamoxi-fen (20 mg/day) to women at risk can reduce breast cancer incidence by ap-proximately 50 % but is associated with an increased risk of developing endo-metrial cancer and venous thromboem-bolic events. Since these adverse effects may be dose related, we investigated the effect of tamoxifen on several bio-markers when the drug was given at doses lower than those currently in use. Methods: In two sequential experi-ments, 127 healthy hysterectomize
Background: Adherence to adjuvant tamoxifen therapy is suboptimal, and acceptance of tamoxifen for p...
Purpose: Endoxifen concentrations have been associated with breast cancer recurrence in tamoxifen-tr...
Levels of endoxifen, the most active metabolite of tamoxifen, vary by the highly polymorphic cytochr...
Background: Results of a clinical trial recently completed in the United States indicate that admini...
Tamoxifen reduces the risk of breast cancer in women at high risk for the disease but increases the ...
The combination of hormone replacement therapy (HRT) and low-dose tamoxifen may retain the benefits ...
Background: Tamoxifen reduces the risk of breast cancer in women at high risk for the disease but in...
The aim of this study was to determine the effects of low doses of tamoxifen (5 and 10 mg/day) for 5...
Endoxifen is the major mediator of tamoxifen effect and endoxifen levels <15 nmol/L may be associate...
Purpose: Both therapeutic and adverse effects of tamoxifen may be related to its tissue concentratio...
Purpose: Both therapeutic and adverse effects of tamoxifen may be related to its tissue concentratio...
PURPOSE: The combination of hormone replacement therapy (HRT) and low-dose tamoxifen may retain the ...
That tamoxifen increases the overall and recurrence-free survival of appropriately selected patients...
Background: Tamoxifen citrate is being evaluated for primary prevention of breast cancer, but this d...
Background and Purpose: Low-dose tamoxifen and fenretinide, a vitamin A derivative, have both shown ...
Background: Adherence to adjuvant tamoxifen therapy is suboptimal, and acceptance of tamoxifen for p...
Purpose: Endoxifen concentrations have been associated with breast cancer recurrence in tamoxifen-tr...
Levels of endoxifen, the most active metabolite of tamoxifen, vary by the highly polymorphic cytochr...
Background: Results of a clinical trial recently completed in the United States indicate that admini...
Tamoxifen reduces the risk of breast cancer in women at high risk for the disease but increases the ...
The combination of hormone replacement therapy (HRT) and low-dose tamoxifen may retain the benefits ...
Background: Tamoxifen reduces the risk of breast cancer in women at high risk for the disease but in...
The aim of this study was to determine the effects of low doses of tamoxifen (5 and 10 mg/day) for 5...
Endoxifen is the major mediator of tamoxifen effect and endoxifen levels <15 nmol/L may be associate...
Purpose: Both therapeutic and adverse effects of tamoxifen may be related to its tissue concentratio...
Purpose: Both therapeutic and adverse effects of tamoxifen may be related to its tissue concentratio...
PURPOSE: The combination of hormone replacement therapy (HRT) and low-dose tamoxifen may retain the ...
That tamoxifen increases the overall and recurrence-free survival of appropriately selected patients...
Background: Tamoxifen citrate is being evaluated for primary prevention of breast cancer, but this d...
Background and Purpose: Low-dose tamoxifen and fenretinide, a vitamin A derivative, have both shown ...
Background: Adherence to adjuvant tamoxifen therapy is suboptimal, and acceptance of tamoxifen for p...
Purpose: Endoxifen concentrations have been associated with breast cancer recurrence in tamoxifen-tr...
Levels of endoxifen, the most active metabolite of tamoxifen, vary by the highly polymorphic cytochr...